Finance
AIDS vaccine developer reports increased cash due to financing
Published in Vaccine Weekly, December 10th, 2003
During the quarter, cash and cash equivalents increased by $2.2 million to an ending balance of $8.1 million at September 30, 2003, from $5.9 million at June 30, 2003. The increase in cash and cash equivalents was primarily due to completion of an equity financing by the company in September 2003 that generated gross proceeds of $4.0 million, partially offset by cash used for operating expenses and non-recurring restructuring expenses.
Approximately $0.4 million of cash used during the third quarter was for one-time expenses related to the company's...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2003-12-10)
More Articles from Vaccine Weekly
- Smallpox Vaccine
Eosinophilic-lymphocytic myocarditis proven after smallpox vaccination - Vaccine Adjuvant
Role of adjuvants in vaccine immunogenicity reviewed - DNA Vaccine
Genetic immunization using pDNA-coated nanoparticles detailed - Japanese Encephalitis
Chimeric attenuated vaccine protects against Japanese encephalitis - Leishmaniasis
Histone H1 antigen protects against cutaneous leishmaniasis in monkeys - West Nile Virus
West Nile/dengue virus vaccine protect monkeys from West Nile virus - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
